# OnCo record nelarabine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nelarabine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nelarabine" ;
  schema:name "Nelarabine"@en ;
  schema:alternateName "Atriance"@en, "Arranon" ;
  schema:description "Nelarabine (Arranon) is an infusion for T-cell acute lymphoblastic leukaemia and lymphoma that has come back after at least two other treatments; it is now also added to first-line therapy for children with T-cell leukaemia."@en ;
  schema:url <https://onco.cc/drugs/nelarabine/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nelarabine> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nelarabine>, <https://www.cancer.gov/about-cancer/treatment/drugs/nelarabine>, <https://www.ema.europa.eu/en/medicines/human/EPAR/atriance> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Purine nucleoside prodrug (antimetabolite)" ;
  onco:approval "US 2005: Relapsed or refractory T-ALL and T-LBL after at least two regimens (accelerated)", "EU 2007: T-ALL and T-LBL after at least two regimens (Atriance)" ;
  onco:acceleratedApproval "US 2005-10-28: Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens" ;
  onco:acceleratedApprovalConfirmed "US 2019-07-31: Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-high-risk/>, <https://onco.cc/cancers/all-paediatric-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/sandoz/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/> .